Celgene & Juno: The Latest in a Bumper Crop of Biotech M&A?


Celgene is on a shopping spree this year: First, it bought Impact Biomedicines for $1.1 billion at the start of the month, and today it announced that it will buy Juno Therapeutics for $87 a share in cash, or $9 billion. Rumors of a Juno deal leaked last week, so some analysts had already come out in favor of the combination .



from Biotech News